NCT02677116 2020-05-20A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With CancerEli Lilly and CompanyPhase 1 Completed68 enrolled 26 charts
NCT01199822 2017-04-14Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsEli Lilly and CompanyPhase 1 Completed16 enrolled 15 charts